Aprea Therapeutics, Inc. (APRE)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Grant revenue | 118,111 | 162,463 | 354,621 | 561,574 |
| Research and development | 1,912,213 | 2,483,066 | 2,846,399 | 2,557,679 |
| General and administrative | 1,593,671 | 1,764,979 | 1,605,238 | 1,850,819 |
| Total operating expenses | 3,505,884 | 4,248,045 | 4,451,637 | 4,408,498 |
| Loss from operations | -3,387,773 | -4,085,582 | -4,097,016 | -3,846,924 |
| Interest income, net | 178,027 | 204,726 | 348,741 | 382,374 |
| Foreign currency (loss) gain | -29,124 | -51,803 | -35,494 | -5,502 |
| Total other income | 148,903 | 152,923 | 313,247 | 376,872 |
| Net loss | -3,238,870 | -3,932,659 | -3,783,769 | -3,470,052 |
| Foreign currency translation | -1,681 | 643 | 23,557 | -1,948 |
| Total comprehensive loss | -3,240,551 | -3,932,016 | -3,760,212 | -3,472,000 |
| Earnings per share, basic | -0.53 | -0.66 | -0.64 | -0.58 |
| Earnings per share, diluted | -0.53 | -0.66 | -0.64 | -0.58 |
| Weighted average number of shares outstanding, basic | 6,083,329 | 5,993,866 | 5,939,755 | 5,937,291 |
| Weighted average number of shares outstanding, diluted | 6,083,329 | 5,993,866 | 5,939,755 | 5,937,291 |